Results of surgical treatment of malignant kidney tumors based on the materials of urology departments of the Siberian State Medical University clinics

Aim. To analyze the results of treatment of patients with kidney tumors in urology departments of the Siberian State Medical University clinics.

Materials and methods. The number of patients with kidney tumors hospitalized in the urology department of the general surgery clinic was 7–10 % of the total annual number of surgical interventions in the urology department. We analyzed 132 cases of malignant kidney tumors. All patients went through imaging and laboratory studies.

Results. Treatment results are known in 125 (94.0 %) patients. Mean age of patients was 57.9 years (27 to 86), there were 77 men and 55 women (1.4:1 ratio). Mean tumor size was 6.5 ± 3.6 cm, no significant differences were observed between men and women. Radical nephrectomy was performed in 75 (56.8 %) patients, kidney resection in 57 (43.2 %) patients. Tumor size in nephrectomy cases was 8.2 ± 3.7 cm and 4.3 ± 2.1 cm in kidney resection (p <0.05). In patients with larger tumors five-year survival was lower: tumor size £4 cm was associated with five-year survival of 79.6 %, while tumor size >7 cm with only 36.9 % (p = 0.001).

In our study, 23 (17.4 %) patients with inferior vena cava thrombosis were operated on: 11 (8.3 %) men, 12 (9.1 %) women. Mean age of patients with inferior vena cava thrombosis was 57.2 years (between 35 and 74 years). In this group of patients, mean tumor size was 10.8 ± 4.1 cm (between 4.2 and 19). Based on TNM classification, tumors were classified as follows: T3b stage – 17 (12.9 %), T4 stage – 6 (4.5 %), N0 – 15 (11.4 %), N+ – 8 (6.1 %). Left kidney was affected in 6 (4.5 %) cases, right kidney was affected in 17 (12.9 %) cases. Type of surgery performed in this group of patients was classified as: radical nephrectomy with thrombectomy and lymphadenectomy, one case included resection of the inferior vena cava with a section reconstructed using a xenopericardial transplant. Mean surgery duration was 212.4 ± 52.3 (130–320) minutes. Mean blood loss volume was 1177.0 ± 933.4 (100–4600) ml. Postoperative complications were observed in 35 (21.2 %) patients. Overall five-year survival for patients with malignant kidney tumors was 61.8 %, for patients with tumor thrombosis it was 31.3 %.

Conclusion. Surgical treatment of patients with malignant kidney tumors allows to significantly improve patients’ survival preserving quality of life.

1. Clinical onkourologiya. Ed.: B.P. Matveev. Moscow: ABV-press, 2011. (In Russ.).

2. Chen W., Zheng R., Baade P.D. et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66(2):115–32. DOI: 10.3322/caac.21338

3. Hötker A.M., Karlo C.A., Zheng J. et al. Clear cell renal cell carcinoma: associations between CT features and patient survival. AJR Am J Roentgenol 2016;206(5):1023–30. DOI: 10.2214/AJR.15.15369

4. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009;373(9669):1119–32. DOI: 10.1016/S0140-6736(09)60229-4

5. Mirza М. Management of small renal masses in the older adult. Clin Geriatr Med 2015;31(4):603–13. DOI: 10.1016/j.cger.2015.06.005

6. Guidelines. European Association of Urology, 2020.

7. Matveev V.B., Markova A.S. Renal cell carcinoma: What’s new in 2018. Onkourologiya = Cancer Urology 2018;14(4):48–52. (In Russ.). DOI: 10.17650/1726-9776-2018-14-4-48-52

8. Humphrey P.A., Moch H., Cubilla A.L. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016;70(1):106–19. DOI: 10.1016/j.eururo.2016.02.028

9. Liungberg B., Bensalah K., Canfield S. et al. EAU guidelines on renal cell carcinoma. Eur Urol 2015;67(5):913–24. DOI: 10.1016/j.eururo.2015.01.005

10. Schukin D.V., Iliukhin Yu.A. Surgery of tumor thrombi from inferior vena cava in renal cell carcinoma. Belgorod: The Belgorod regional printing house, 2007. 196 p. (In Russ.).

11. Diagnosis and surgical management of renal tumors. Eds.: M.A. Gorin, M.E. Allaf. Springer International Publishing AG, part of Springer Nature, 2019.

12. Hsieh J.J., Purdue M.P., Signoretti S. et al. Renal cell carcinoma Nat Rev Dis Primers 2017;3:17009. DOI: 10.1038/nrdp.2017.9

13. Jakubovskis M., Kojalo U., Steinbrekera B. et al. Renal cell carcinoma trends in Latvia: incidence, mortality, and survival rates. Population-based study. Cent European J Urol 2019;72(4):344–50. DOI: 10.5173/ceju.2019.0018

14. Reix B., Bernhard J.C., Patard J.J. et al. Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: a collaborative international study from the French kidney cancer research network UroCCR. Prog Urol 2018;28(3):146–55. DOI: 10.1016/j.purol.2017.12.004

15. Davidov M.I., Matveev V.B., Matveev B.P. Operations on the inferior vena cava at patients with renal cell carcinoma. Materials of the VI Russian Oncological Conference. Available at: http://www.rosoncoweb.ru/library/congress/ru/06/21.php. (In Russ.).

16. Pereverzev A.S. Surgery of tumours of a kidney and the upper urinary tract. Kharkov: Lora Medpharm, 1997. 392 p. (In Russ.).

17. Lambert E.H., Pierorazio P.M., Shabsigh A. et al. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology 2007;69(6):1054–8. DOI: 10.1016/j.urology.2007.02.052

18. Gonzalez J., Gorin M.A., Garcia-Roig M., Ciancio G. Inferior vena cava resection and reconstruction: technical considerations in the surgical management of renal cell carcinoma with tumor thrombus. Urol Oncol 2014;32(1):34.e19–26. DOI: 10.1016/j.urolonc.2013.01.004

19. Volkova M.I., Chernyaev V.A., Begaliev A.K. et al. Safety of left renal vein ligation during circumferential resection of the inferior vena cava in patients with cancer of the right kidney and venous tumoral thrombosis. Onkourologiya = Cancer Urology 2018;14(4):30–6. (In Russ.). DOI: 10.17650/1726-9776-2018-14-4-30-36.

20. Kotov S.V., Kirienko A.I., Yusufov A.G. et al. Intraoperative and oncological results of treating patients with renal cell carcinoma and venous tumor thrombus. Onkourologiya = Cancer Urology 2018;14(1): 57–67. (In Russ.). DOI: 10.17650/1726-9776-2018-14-1-57-67